VAP-1 Antibody (TK8-14): sc-33670

VAP-1 Antibody (TK8-14) is a mouse monoclonal IgG2a antibody that detects VAP-1 in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). Vascular adhesion protein-1 (VAP-1) plays a crucial role in the immune response by facilitating lymphocyte adhesion to vascular endothelium, essential for immune cell migration from bloodstream to lymphoid tissues and inflammation sites. VAP-1 is primarily located on endothelial cell surfaces, where expression significantly increases under inflammatory conditions. VAP-1 functions as both a monoamine oxidase and adhesion molecule, mediating lymphocyte adhesion and promoting recirculation. VAP-1 exists predominantly as a homodimer in vivo, and proper glycosylation is vital for inflammatory function. VAP-1 is expressed in various smooth muscle cells, although lymphocyte binding is not supported in these cells. Soluble VAP-1 is detectable in circulation, with elevated levels observed in patients with inflammatory liver diseases, highlighting potential as an inflammation biomarker.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VAP-1 Antibody (TK8-14) References:

1. VAP-1-mediated M2 macrophage infiltration underlies IL-1β- but not VEGF-A-induced lymph- and angiogenesis.  |  Nakao, S., et al. 2011. Am J Pathol. 178: 1913-21. PMID: 21435467
2. VAP-1/SSAO plasma activity and brain expression in human hemorrhagic stroke.  |  Hernandez-Guillamon, M., et al. 2012. Cerebrovasc Dis. 33: 55-63. PMID: 22133888
3. VCAM-1 and VAP-1 recruit myeloid cells that promote pulmonary metastasis in mice.  |  Ferjančič, Š., et al. 2013. Blood. 121: 3289-97. PMID: 23407548
4. Increased Vascular Adhesion Protein 1 (VAP-1) Levels are Associated with Alternative M2 Macrophage Activation and Poor Prognosis for Human Gliomas.  |  Chang, SJ., et al. 2020. Diagnostics (Basel). 10: PMID: 32349342
5. Circulating vascular adhesion protein-1(VAP-1): a possible biomarker for liver fibrosis associated with chronic hepatitis B and C.  |  Öksüz, Z., et al. 2020. Braz J Microbiol. 51: 1757-1763. PMID: 32959205
6. SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer's Disease.  |  Unzeta, M., et al. 2021. Int J Mol Sci. 22: PMID: 33805974
7. Vascular Adhesion Protein-1 (VAP-1)/Semicarbazide-Sensitive Amine Oxidase (SSAO): A Potential Therapeutic Target for Atherosclerotic Cardiovascular Diseases.  |  Li, H., et al. 2021. Front Pharmacol. 12: 679707. PMID: 34322017
8. Downregulation of VAP-1 in OSCC suppresses tumor growth and metastasis via NF-κB/IL-8 signaling and reduces neutrophil infiltration.  |  Xu, Q., et al. 2022. J Oral Pathol Med. 51: 332-341. PMID: 35174543
9. Vascular adhesion protein-1 (VAP-1) in vascular inflammatory diseases.  |  Danielli, M., et al. 2022. Vasa. 51: 341-350. PMID: 36200383
10. Association Between Vascular Adhesion Protein-1 (VAP-1) and MACE in Patients with Coronary Heart Disease: A Cohort Study.  |  Zhang, Y., et al. 2024. J Inflamm Res. 17: 3603-3615. PMID: 38855169

The preferred VAP-1 antibody is VAP-1 Antibody (A-8): sc-166713.